A new contender in the global weight-loss drug market is emerging from China. Jiangsu-based Hengrui Pharma, together with its U.S. partner Kailera Therapeutics, has announced encouraging late-stage trial results for HRS9531, an investigational obesity treatment showing comparable efficacy to leading therapies on the market.
In a 48-week Phase 3 trial, patients on HRS9531 lost an average of 18% of their body weight, with that number rising to 19% among those who completed the trial. While Eli Lilly’s Zepbound (tirzepatide) demonstrated 21% weight loss in a longer trial, the Hengrui study suggests the potential for higher outcomes, especially since the highest dose level of HRS9531 has not yet been fully evaluated.
Importantly, the trial data indicate that patients were still losing weight when the study ended, suggesting that longer treatment durations or higher doses could yield even more effective results. Hengrui plans to seek regulatory approval in China soon, while Kailera prepares for global clinical trials to pursue approvals outside of China.
“Today’s treatments are pretty much capped at about 20% weight loss,” said Jamie Coleman, Chief Commercial Officer at Kailera and former U.S. brand lead for Zepbound at Lilly. “Our goal is to maximize that efficacy, go beyond that.”
Bridging Innovation Across Borders
HRS9531, which Kailera refers to as KAI-9531, is a dual GLP-1/GIP receptor agonist, similar in mechanism to Zepbound. In a prior higher-dose trial, the treatment achieved 22.8% weight loss over 36 weeks, reinforcing its potential as a strong addition to the obesity treatment landscape.
Although the most recent study enrolled 567 patients, smaller than a typical global Phase 3 trial, it lays a strong foundation for international development. Kailera, backed by $400 million in private funding, holds ex-China rights to HRS9531 and three other Hengrui assets. The company is already in talks with contract manufacturers to ensure production readiness for future global demand.
“We intend to focus and compete where weight loss matters the most,” Coleman noted. “There’s a high level of unmet need in people that need to lose more than what current therapies provide.”
China’s Growing Role in Global Biotech
This development reflects a broader trend: China’s growing role in global pharmaceutical innovation. In recent years, Chinese biotech companies have become key partners in the international drug development ecosystem. U.S. firms including Merck, Regeneron, AstraZeneca, and Lilly have licensed promising molecules from Chinese developers, signaling confidence in China’s R&D capabilities and scientific rigor.
In December, Merck licensed an oral GLP-1 compound from Hansoh Pharma for $112 million upfront, followed by Regeneron’s $80 million deal with the same firm in June. These collaborations exemplify the increasingly global nature of biotech innovation, where strong science and execution transcend geographic boundaries.
Looking Ahead
While HRS9531 is still in the early stages of global development, its clinical profile and safety tolerability offer promise for the future. Kailera is positioning the drug for patients with more advanced weight-loss needs, those who may benefit from efficacy beyond current benchmarks.
This moment isn’t about competition, it’s about opportunity. With more nations contributing to breakthroughs in medicine, the world is poised to benefit from diverse innovation pipelines and broader access to life-changing therapies.
HRS9531’s success could mark a meaningful step in a global collaboration story, one where biotech talent from China and the U.S. combine strengths to tackle some of the most pressing health challenges of our time.
Exciting times for global health innovation! Hengrui Pharma is showing that collaboration knows no borders. Here’s to breakthroughs that make a real difference in people’s lives!